In some other cancer types, high TMB in concert with the expression of PD-L1 was considered as an effective biomarker for ICB therapy, and TMB can be associated with the efficacy of ICB of the combination with ipilimumab and nivolumab alone, where high-TMB tumors are with potential immunogenicity; however, the infiltration and/or activation of T cell is CTLA-4 dependently controlled [47]. The gene discussed is CTLA4; the disease is cancer.